Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A bioequivalence study assessing the new formulation F8 compared to the original formulation F1 of tesamorelin

Next Previous
X
Search
Trial Profile

A bioequivalence study assessing the new formulation F8 compared to the original formulation F1 of tesamorelin

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tesamorelin (Primary)
  • Indications HIV-associated lipodystrophy syndrome
  • Focus Pharmacokinetics

    • Most Recent Events

    • 06 Feb 2024 According to a Theratechnologies media release, the company has received the Complete Response Letter issued by the U.S. Food and Drug Administration in response to the Companys supplemental Biologics License Application for the F8 formulation of tesamorelin.
    • 23 Jan 2024 According to a Theratechnologies media release, the company has received correspondence from the U.S. Food and Drug Administration (FDA) regarding the Company's supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin.
    • 25 Sep 2023 According to a Theratechnologies media release, company expects to receive an acknowledgment letter of the sBLA application within 30 days along with a Prescription Drug User Fee Act (PDUFA) goal date.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top